Literature DB >> 30707244

[Two case reports on resistant hypertension].

C Beger1, H Haller1,2, F P Limbourg3,4.   

Abstract

Primary aldosteronism (PA) is a frequent cause of resistant hypertension. The clinical presentation is heterogeneous, but a suppressed or low normal renin (especially with ACE inhibitors or sartans) should raise suspicion for primary aldosteronism, even when aldosterone levels are in the normal range. Diagnosis of unilateral hormone production from an adrenal adenoma (Conn syndrome), which is curable by surgery, requires adrenal vein sampling, which should be performed in experienced centers.

Entities:  

Keywords:  Adrenalectomy; Aldosterone; Hyperaldosteronism; Hypertension, secondary; Renin

Mesh:

Substances:

Year:  2019        PMID: 30707244     DOI: 10.1007/s00108-019-0563-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  Primary aldosteronism.

Authors:  J W CONN
Journal:  J Lab Clin Med       Date:  1955-04

2.  Rapid Diagnosis of Primary Aldosteronism: Oxymoron or One Small Step?

Authors:  Morris J Brown
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

3.  Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.

Authors:  Silvia Monticone; Jacopo Burrello; Davide Tizzani; Chiara Bertello; Andrea Viola; Fabrizio Buffolo; Luisa Gabetti; Giulio Mengozzi; Tracy A Williams; Franco Rabbia; Franco Veglio; Paolo Mulatero
Journal:  J Am Coll Cardiol       Date:  2017-04-11       Impact factor: 24.094

4.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

5.  Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing.

Authors:  Sue Hood; John Cannon; Roger Foo; Morris Brown
Journal:  Clin Med (Lond)       Date:  2005 Jan-Feb       Impact factor: 2.659

6.  Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma.

Authors:  Gian Paolo Rossi; Anna Belfiore; Giampaolo Bernini; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Gaetana Palumbo; Damiano Rizzoni; Ermanno Rossi; Enrico Agabiti-Rosei; Achille C Pessina; Franco Mantero
Journal:  Hypertension       Date:  2007-06-25       Impact factor: 10.190

7.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

8.  Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.

Authors:  Gian Paolo Rossi; Maurizio Cesari; Cesare Cuspidi; Giuseppe Maiolino; Maria Verena Cicala; Valeria Bisogni; Franco Mantero; Achille C Pessina
Journal:  Hypertension       Date:  2013-05-06       Impact factor: 10.190

9.  Clinical value of plasma renin estimation in the management of hypertension.

Authors:  Morris J Brown
Journal:  Am J Hypertens       Date:  2014-08       Impact factor: 2.689

10.  An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism.

Authors:  Gian Paolo Rossi; Richard J Auchus; Morris Brown; Jacques W M Lenders; Mitsuhide Naruse; Pierre Francois Plouin; Fumitoshi Satoh; William F Young
Journal:  Hypertension       Date:  2013-11-11       Impact factor: 10.190

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.